Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.

Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M.

PLoS One. 2011;6(9):e25341. doi: 10.1371/journal.pone.0025341. Epub 2011 Sep 29.

2.

Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.

Terry S, Yang X, Chen MW, Vacherot F, Buttyan R.

J Cell Biochem. 2006 Oct 1;99(2):402-10. Review.

PMID:
16741972
3.

Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.

Kobayashi T, Inoue T, Kamba T, Ogawa O.

Int J Mol Sci. 2013 Jul 26;14(8):15615-35. doi: 10.3390/ijms140815615. Review.

4.

Glycogen synthase kinase-3: a potential preventive target for prostate cancer management.

Li B, Thrasher JB, Terranova P.

Urol Oncol. 2015 Nov;33(11):456-63. doi: 10.1016/j.urolonc.2015.05.006. Epub 2015 Jun 4. Review.

5.

"Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.

Sharifi N, McPhaul MJ, Auchus RJ.

J Investig Med. 2010 Dec;58(8):938-44. doi: 10.231/JIM.0b013e3181ff6bb8. Review.

6.

Posttranslational modification of the androgen receptor in prostate cancer.

van der Steen T, Tindall DJ, Huang H.

Int J Mol Sci. 2013 Jul 16;14(7):14833-59. doi: 10.3390/ijms140714833. Review.

7.

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.

Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD, Mazar AP.

Clin Cancer Res. 2017 Apr 15;23(8):1891-1897. doi: 10.1158/1078-0432.CCR-15-2240. Epub 2017 Jan 4. Review.

PMID:
28053024
8.

Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme.

Atkins RJ, Stylli SS, Luwor RB, Kaye AH, Hovens CM.

J Clin Neurosci. 2013 Sep;20(9):1185-92. doi: 10.1016/j.jocn.2013.02.003. Epub 2013 Jun 12. Review.

PMID:
23768967
9.

Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Nadiminty N, Gao AC.

World J Urol. 2012 Jun;30(3):287-95. doi: 10.1007/s00345-011-0771-3. Epub 2011 Oct 19. Review.

PMID:
22009116
10.

GSK-3 inhibition: achieving moderate efficacy with high selectivity.

Avrahami L, Licht-Murava A, Eisenstein M, Eldar-Finkelman H.

Biochim Biophys Acta. 2013 Jul;1834(7):1410-4. doi: 10.1016/j.bbapap.2013.01.016. Epub 2013 Jan 29. Review.

PMID:
23369789
11.

Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS.

Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA.

J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6. Epub 2006 Dec 16. Review.

PMID:
18040831
12.

Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.

Pandey MK, DeGrado TR.

Theranostics. 2016 Feb 17;6(4):571-93. doi: 10.7150/thno.14334. eCollection 2016. Review.

Supplemental Content

Support Center